Advances in Neuro-oncology

Brain tumors are some of the most complicated forms of cancer to treat due to their extremely sensitive location. Surgery is the first choice when possible, as it guarantees removal of the tumor. Brain surgery is, however, an extremely invasive procedure and requires weeks to months of recovery time for the patient. Radiation therapy offers a minimally invasive alternative, but it comes with its own set of side effects and complications, including cognitive issues, fatigue, and hair and scalp problems, among others. According to the National Brain Tumor Society, however, only four drugs and one device have been U.S. Food and Drug Administration (FDA)-approved to treat brain tumors in the past 30 years.

Spotlight

Alliance Family of Companies

Alliance Family of Companies is the largest provider of in-home video EEGs in the country. Alliance strives to condense the patient care cycle, allowing for strong physician relationships and better patient experiences. We have the audacious goal of innovating the delivery of healthcare services that enable doctors to create treatment plans and improve our patients quality of life.

OTHER ARTICLES
Medical

Immunology: A New Frontier in Medical Science

Article | July 14, 2022

Introduction Recent developments in the bioengineering of monoclonal antibodies (mAbs) have revolutionized the treatment of numerous rheumatic and immunological disorders. Currently, several immunological disorders are successfully being targeted and treated using innovative medical techniques such as immunotherapy. Leading companies are increasingly investing in research activities to expand the usage and application of immunology for the treatment of various infectious diseases, including multiple sclerosis, inflammatory bowel disorders, lupus, and psoriasis, leading companies are increasingly investing in research activities. Today, the efforts of researchers in immunology, with a long history of study and research, have borne fruit, as bioengineered mAbs are now being employed in clinical practices. Accelerating Investments: Paving the Way for Immunology The increasing prevalence of infectious diseases, cancer, and immune-mediated inflammatory disorders (IMIDs) is raising the need for more precise classification and an in-depth understanding of the pathology underlying these ailments. Numerous leaders in the biotechnology domain are thus focusing on undertaking numerous strategies, such as new facility launches and collaborations, to address the need by finding deeper inroads into immunology and its use in disease treatments. For instance, in 2022, the University of Texas MD Anderson Cancer Center announced the launch of a visionary research and innovation hub, the James P. Allison Institute, to find new roads in immunotherapy, develop new treatments, and foster groundbreaking science. These developments will result in better diagnosis through the use of selective biomarkers, and early detection of fatal diseases and their treatment, which will prevent complications from happening. Also, the identification of high-risk populations through a deeper understanding of genetic and environmental factors can assist in the prevention of disease through immunotherapy. The Way Forward Immunology has led to the development of biotechnology, making it possible to develop novel drugs and vaccines, as well as diagnostic tests, that can be used to prevent, diagnose, and treat a wide range of autoimmune, infectious, and cancerous diseases. With the rapid advancement in technology and the integration of artificial intelligence, immunology is finding its way into an array of domains and industries, encompassing several research areas including medicine, pharmaceuticals, agriculture, and space. Today, not only researchers but also leading biotech and pharmaceutical companies have recognized that conventional therapies with pharmaceutical and chemical products are being replaced by products derived from immunology. This is because they work well for health problems, are environmentally friendly, and are also emerging as a wealth-generating business in the medical field.

Read More
MedTech

Next-Gen Gene Therapy to Counter Complex Diseases

Article | July 11, 2022

Gene therapy has historically been used to treat disorders with in-depth knowledge caused by a single genetic mutation. Thanks to the introduction of new generation technologies, the potential of gene therapy is expanding tAo treat diseases that were previously untreatable. Evolution of Gene Therapy One of the major success stories of the twenty-first century has been gene therapy. However, it has not been the same in the past. The field's journey to this point has been long and mostly difficult, with both tragedy and triumph along the way. Initially, genetic disorders were thought to be untreatable and permanently carved into the genomes of individuals unfortunate enough to be born with them. But due to the constant technological advancement and research activities, gene therapy now has the potential to treat various genetic mutation-causing diseases with its ability to insert a new copy and replace faulty genes. Gene Therapy is Finding New Roads in the Medical Sector Gene therapy can help researchers treat a variety of conditions that fall under the general heading of epilepsy, instead of only focusing on a particular kind of disorder brought on by a genetic mutation. Following are some of the domains transformed by gene therapy. Neurology – Gene therapy can be used for the treatment of seizures by directly injecting it into the area causing an uncontrolled electrical disturbance in the brain. Furthermore, by using DNA sequences known as promoters, gene therapy can be restricted to specific neurons within that area. Ophthalmology – Genetic conditions such as blindness can be caused due to the mutation of any gene out of over 200 and resulting in progressive vision loss in children. With advanced gene therapies such as optogenetics, lost photoreceptor function can be transferred to the retinal cells, which are responsible for relaying visual information to the brain. This might give patients the ability to navigate in an unknown environment with a certain level of autonomy. The Future of Gene Therapy The news surrounding gene therapy has been largely favorable over the past few years, with treatment after treatment obtaining regulatory approvals, successful clinical trials, and garnering significant funds to begin development. With more than 1,000 clinical trials presently underway, the long-awaited gene therapy revolution might finally be here.

Read More
MedTech

How to Choose a Reliable Biotech Clinical Trial Management System?

Article | October 7, 2022

Introduction The medical and life-science industries are experiencing a robust transformation with the increasing prevalence of various types of diseases, including infectious diseases, chronic disorders, and acute conditions around the world. As a result, a significant rise in demand for more effective therapeutic drugs and bionics is being witnessed, leading to a swift increase in the number of clinical trials. For a successful trial, it is important for biotech companies to ensure the data submitted to regulatory bodies regarding clinical trials is accurate, reliable, and definitive from an ethical point of view. A reliable clinical trial management system plays a vital role in collecting, monitoring, and managing clinical data. The availability of high-quality clinical data also helps clinical research institutions make efficient treatment decisions and provide proper patient care. Hence, a number of biotech companies and research organizations are focusing on leveraging innovative clinical trial management solutions to handle a large amount of data, particularly in multi-center trials, and generate reliable, high-quality, and statistically sound data from clinical trials. However, selecting the most appropriate and reliable clinical trial management system is vital for the clinical trial's success. Let's see some of the steps that will assist these firms in choosing the right CTMS. Key Steps for Selecting Right Biotech Clinical Trial Management System Prioritize Study Needs Considering and prioritizing study needs is a crucial step in choosing the most reliable clinical trial management system for biotech companies. Prioritizing helps them to identify a solution that improves the study's quality and removes uncertainty for researchers when faced with difficult choices. Hence, biotech and life-science organizations should choose a clinical trial system that is simple to use, well-organized, and suitably designed to minimize the number of clicks required to complete a task. Select CTMS with Multiple Integrations Integrated clinical trial management systems provide the best value for the companies’ funds as they guarantee the smooth functioning of research protocols. In addition, integrations are necessary to fully understand the importance and advantages of clinical trial management software for ensuring smooth transitions between site management and data collection. Biotech and clinical research should look for CTMS platforms that can integrate with electronic medical record (EMR) platforms and clinical research process content (CRPC) billing grids. This will allow them to use the same billing designations and ensure compliance while minimizing the need for duplicate processes. Ensure System Compliance and Security Clinical research organizations need to adhere to a plethora of complex regulations in order to ensure compliance with one of the most challenging environments of principles, which is information security and privacy. Security and system compliance are vital aspects of choosing the right CTMS solutions for biotech firms as they assist in building trust and form a part of the system’s duties. While selecting CTMS systems, it is essential for companies engaged in clinical research to ensure that these platforms are able to configure both, group and individual permissions, along with having a data backup and recovery plan for hosted systems. This will allow companies to assess the privacy and security implications of research and anticipate complications that may arise in each phase of the project. Assess the Scalability Choosing a scalable CTMS that can accommodate various types of fluctuations and expansions enables biotech and clinical firms to quickly adapt to fast-changing trends and demand spikes while reducing maintenance costs and enhancing user agility. As scalability also means secure and expanded data storage, these businesses should instead use SaaS solutions than manually manage an ever-growing collection of hard drives. The right CTMS ensures accommodating the firm’s availability requirements without incurring the capital costs associated with expanding a physical infrastructure. The Closing Thought A well-executed and successful clinical trial involves multiple stages and processes. Several quality controls and stringent adherence to regulations are essential for the steps, along with efficient cross-departmental processes and procedures. Incorporating the right CTMS paves the way for paperless data collection, regulatory filing, and fiscal management tools for biotech researchers and administrative personnel.

Read More
Medical

Nanostructures: Emerging as Effective Carriers for Drug Delivery

Article | July 14, 2022

Natural remedies have been employed in medicine since antiquity. However, a large number of them fail to go past the clinical trial stages. In vivo instability, poor solubility and bioavailability, a lack of target-specific delivery, poor absorption, and side effects of the medication are only a few of the problems caused by the use of large-sized materials in drug administration. Therefore, adopting novel drug delivery systems with targeted medications may be a solution to address these pressing problems. Nanotechnology has received tremendous attention in recent years and has been demonstrated to help blur the boundaries between the biological and physical sciences. With great success, it plays a vital part in enhanced medication formulations, targeted venues, and controlled drug release and delivery. Limitations of Traditional Delivery Trigger the Adoption of Nanoparticles The field of nanotechnology and the creation of drug formulations based on nanoparticles is one that is expanding and showcasing great potential. It has been thoroughly researched in an effort to develop new methods of diagnosis and treatment and to overcome the limitations of several diseases' current therapies. As a result, nanoparticles are being used to improve the therapeutic effectiveness and boost patient adherence to treatment by increasing medication bioavailability, drug accumulation at a particular spot, and reducing drug adverse effects. The nanoparticles could be transformed into intelligent systems housing therapeutic and imaging agents by manipulating their surface properties, size, correct drug load, and release with targeted drug delivery. Nanostructures facilitate the release of combination medications at the prescribed dose since they remain in the blood circulation system for a long time. Therefore, they result in fewer plasma fluctuations with decreased side effects. Due to their nanoscale, these structures can easily enter the tissue system, promote the absorption of drugs by cells, make medication administration more effective, and ensure that the medicine acts at the targeted location. The Way Ahead Nanomedicine and nano-delivery systems are a comparatively new but fast-evolving science in which nanoscale materials are used as diagnostic tools to deliver drug molecules at precisely targeted sites in a controlled manner. It is finding applications for the treatment of diseases such as cardiovascular, neurodegenerative, cancer, ocular, AIDS, and diabetes, among others. With more research and technological advancement, these drug delivery solutions will open up huge opportunities for companies that work with them.

Read More

Spotlight

Alliance Family of Companies

Alliance Family of Companies is the largest provider of in-home video EEGs in the country. Alliance strives to condense the patient care cycle, allowing for strong physician relationships and better patient experiences. We have the audacious goal of innovating the delivery of healthcare services that enable doctors to create treatment plans and improve our patients quality of life.

Related News

Medical

Precision NanoSystems is Now a Part of Danaher's Life Sciences Platform

Cytiva, Pall Corporation | June 02, 2021

Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall. "PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danaher Group Executive. "As mRNA has matured as a successful technology in some COVID vaccines, we see huge potential for this technology to accelerate other therapies. The work done thus far by the PNI team will also enable our customers at Cytiva and Pall to take a huge step forward in advancing their science to improve the lives of patients." James Taylor, co-founder, and CEO of Precision NanoSystems, says: "Over the last ten years, PNI has been a leading technology company, enabling the development of genetic medicines. Joining Danaher's Life Sciences platform allows our world-class team to accelerate and expand the work we do to support our customers with comprehensive technology platforms and the expertise to manufacture transformative medicines for the benefit of humanity. With the global reach of the Danaher Life Sciences platform and customers who are leaders in biotechnology, this is an incredible opportunity to bring PNI's innovations to market and expand our impact." The overall mRNA therapeutics and vaccines market was growing rapidly and accelerated with the development of COVID-19 mRNA vaccines. It is anticipated that mRNA technology will be used to develop other vaccines and to treat other conditions of high unmet medical need, such as cancer and genetic diseases. At present, most mRNA therapies and other types of genetic medicines in clinical development are designed to be delivered with the help of lipid nanoparticles (LNPs). PNI's Genetic Medicine Toolkit, including its proprietary GenVoyTM LNP delivery platform and NanoAssemblrTM microfluidic-based nanoparticle manufacturing platform, enables the rapid development of genetic medicines. PNI's validated technologies increase the stability, efficacy, yield, and quality of non-viral genetic medication and lower the barrier to develop these essential medicines. PNI is developing a new center of manufacturing excellence in Vancouver, which will proceed as planned. When complete, the biomanufacturing center will further advance Canadian therapeutic and vaccine manufacturing capabilities, broaden the domestic life sciences sector, create new jobs in the region, and foster a new generation of scientific talent. About Pall Pall Corporation may be a filtration, separation, and purification leader providing solutions to meet customers' critical fluid management needs across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety, and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. About Cytiva Cytiva is a global life science leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency, and capacity to research and manufacture workflows, enabling the development, manufacture, and delivery of transformative medicines to patients.

Read More

MedTech

ZS and Seven Bridges Collaborate to Innovate Drug Research

ZS, Seven Bridges | May 07, 2021

ZS and Seven Bridges disclosed a collaboration today that will merge ZS's experience in biomedical testing facilities and data science with Seven Bridges' technology platform, which enables multi-omics analytics through the translational and clinical continuum. The hybrid offers biopharmaceutical and biotechnology firms a one-stop-shop for multi-omics analysis innovation and scalability. ZS and Seven Bridges work together to help clients produce breakthrough science, promote drug development, and improve the probability of approval for potential drug candidates. "Working side by side with our clients to help streamline R&D data and maximize pace and market to enhance patients' lives is at the heart of what we do at ZS," said Aaron Mitchell, principal, and leader of ZS's research and development excellence program. "Our collaboration with Seven Bridges allows our clients, and eventually patients, to gain access to new therapies and diagnostics more quickly." "Drug discovery, translational medicine, and preclinical drug research all require study at the molecular and genomic levels of implementation, and our collaboration with Seven Bridges provides our clients with a new option for innovation and scalable capacity," said John Piccone, principal, and leader of ZS's biomedical research service line. "We are building a talent pool of molecular natives with a strong knowledge of chemistry, data science, and technology to collaborate with our clients in the discovery of potential drug targets, the selection of drug candidates, and the solution of key translational medicine challenges. The integration of the Seven Bridges Platform and experts with the ZS consulting teams results in a modular approach for clients with growing multi-omics data and analytics requirements." "We are delighted to be combining the Seven Bridges platform with ZS's innovative apps for drug discovery and translational medicine. Integrating our multi-omics analysis platform and ARIATM, a centralized solution for molecular and patient-level phenotypic analysis at scale, with their research data lake is a critical requirement for ZS's pharmaceutical clients "said Bruce Press, Seven Bridges' Chief Revenue Officer. About Seven Bridges Seven Bridges allows researchers to derive meaningful insights from genomic and phenotypic data, thereby advancing precision medicine. A compliant analytic platform, intelligently curated content, innovative algorithms, unmatched access to federated data sets, and specialist on-demand technical resources comprise the Seven Bridges Ecosystem. Researchers at the world's leading academic, biotechnology, clinical diagnostic, government, medical centers, and pharmaceutical institutions are using this systematic approach to bioinformatics to maximize R&D effectiveness, improve hypothesis resolution, isolate vital biomarkers, and even transform a failing clinical trial around while also minimizing computational workflow times and data storage costs.

Read More

Research

Chemistry42, an AI System from Insilico, has been Incorporated into UCB's Drug Discovery Programmes

Insilico Medicine | March 15, 2021

Insilico Medicine, an AI drug discovery company, reported that UCB will incorporate Insilico's Chemistry42™ into UCB's inward drug discovery pipeline. UCB's initial appropriation of Insilico Medicine's restrictive innovation will give UCB's researchers the capacity to plan novel hit compounds that fulfill various predefined boundaries quickly and smooth out lead enhancement. With the Chemistry42™ platform, UCB researchers will likewise lessen the endeavors and expenses commonly connected with the plan, testing and commercialization of new drugs. Chemistry42™ v1.0 will be modified and conveyed on UCB's cloud-based supercomputing infrastructure. Chemistry42™ is an adaptable, easy to understand programming platform that incorporates man-made brainpower (AI) strategies with the fields of therapeutic and computational science for the plan of novel little atoms with client characterized druglike physicochemical properties. The platform is an adaptable conveyed web application equipped for running various assignments in equal very quickly. Container coordination and work process the executives consider unsurprising equipment freethinker asset distribution and the execution on one or the other cloud or neighborhood HPC infrastructures. "UCB is one of the leading companies in small molecule drug discovery. It was their insight and approach at the forefront of this science that encouraged us to move into AI-powered chemistry over five years ago and it gives me great pleasure to see UCB among the launch partners of our Chemistry42 operating system," said Alex Zhavoronkov, Ph.D., CEO of Insilico Medicine. "Insilico Medicine has been very responsive in this quickly developing area of science and we are delighted to be one of the launch partners for Chemistry42," Jiye Shi, Global Head of Computer-Aided Drug Design at UCB said. "Our hope is that this platform will further enhance the digital transformation of our drug discovery capabilities for the benefit of patients worldwide." About Insilico Medicine Insilico Medicine develops software that leverages generative models, reinforcement learning (RL), and other modern machine learning techniques to generate new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trial outcomes. The company integrates two business models: providing AI-powered drug discovery services and software through its Pharma.AI platform (www.insilico.com/platform/) and developing its pipeline of preclinical programs. The preclinical program is the result of pursuing novel drug targets and novel molecules discovered through its platforms. Since its inception in 2014, Insilico Medicine has raised over $52 million and received multiple industry awards. About UCB UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Read More

Medical

Precision NanoSystems is Now a Part of Danaher's Life Sciences Platform

Cytiva, Pall Corporation | June 02, 2021

Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall. "PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danaher Group Executive. "As mRNA has matured as a successful technology in some COVID vaccines, we see huge potential for this technology to accelerate other therapies. The work done thus far by the PNI team will also enable our customers at Cytiva and Pall to take a huge step forward in advancing their science to improve the lives of patients." James Taylor, co-founder, and CEO of Precision NanoSystems, says: "Over the last ten years, PNI has been a leading technology company, enabling the development of genetic medicines. Joining Danaher's Life Sciences platform allows our world-class team to accelerate and expand the work we do to support our customers with comprehensive technology platforms and the expertise to manufacture transformative medicines for the benefit of humanity. With the global reach of the Danaher Life Sciences platform and customers who are leaders in biotechnology, this is an incredible opportunity to bring PNI's innovations to market and expand our impact." The overall mRNA therapeutics and vaccines market was growing rapidly and accelerated with the development of COVID-19 mRNA vaccines. It is anticipated that mRNA technology will be used to develop other vaccines and to treat other conditions of high unmet medical need, such as cancer and genetic diseases. At present, most mRNA therapies and other types of genetic medicines in clinical development are designed to be delivered with the help of lipid nanoparticles (LNPs). PNI's Genetic Medicine Toolkit, including its proprietary GenVoyTM LNP delivery platform and NanoAssemblrTM microfluidic-based nanoparticle manufacturing platform, enables the rapid development of genetic medicines. PNI's validated technologies increase the stability, efficacy, yield, and quality of non-viral genetic medication and lower the barrier to develop these essential medicines. PNI is developing a new center of manufacturing excellence in Vancouver, which will proceed as planned. When complete, the biomanufacturing center will further advance Canadian therapeutic and vaccine manufacturing capabilities, broaden the domestic life sciences sector, create new jobs in the region, and foster a new generation of scientific talent. About Pall Pall Corporation may be a filtration, separation, and purification leader providing solutions to meet customers' critical fluid management needs across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety, and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. About Cytiva Cytiva is a global life science leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency, and capacity to research and manufacture workflows, enabling the development, manufacture, and delivery of transformative medicines to patients.

Read More

MedTech

ZS and Seven Bridges Collaborate to Innovate Drug Research

ZS, Seven Bridges | May 07, 2021

ZS and Seven Bridges disclosed a collaboration today that will merge ZS's experience in biomedical testing facilities and data science with Seven Bridges' technology platform, which enables multi-omics analytics through the translational and clinical continuum. The hybrid offers biopharmaceutical and biotechnology firms a one-stop-shop for multi-omics analysis innovation and scalability. ZS and Seven Bridges work together to help clients produce breakthrough science, promote drug development, and improve the probability of approval for potential drug candidates. "Working side by side with our clients to help streamline R&D data and maximize pace and market to enhance patients' lives is at the heart of what we do at ZS," said Aaron Mitchell, principal, and leader of ZS's research and development excellence program. "Our collaboration with Seven Bridges allows our clients, and eventually patients, to gain access to new therapies and diagnostics more quickly." "Drug discovery, translational medicine, and preclinical drug research all require study at the molecular and genomic levels of implementation, and our collaboration with Seven Bridges provides our clients with a new option for innovation and scalable capacity," said John Piccone, principal, and leader of ZS's biomedical research service line. "We are building a talent pool of molecular natives with a strong knowledge of chemistry, data science, and technology to collaborate with our clients in the discovery of potential drug targets, the selection of drug candidates, and the solution of key translational medicine challenges. The integration of the Seven Bridges Platform and experts with the ZS consulting teams results in a modular approach for clients with growing multi-omics data and analytics requirements." "We are delighted to be combining the Seven Bridges platform with ZS's innovative apps for drug discovery and translational medicine. Integrating our multi-omics analysis platform and ARIATM, a centralized solution for molecular and patient-level phenotypic analysis at scale, with their research data lake is a critical requirement for ZS's pharmaceutical clients "said Bruce Press, Seven Bridges' Chief Revenue Officer. About Seven Bridges Seven Bridges allows researchers to derive meaningful insights from genomic and phenotypic data, thereby advancing precision medicine. A compliant analytic platform, intelligently curated content, innovative algorithms, unmatched access to federated data sets, and specialist on-demand technical resources comprise the Seven Bridges Ecosystem. Researchers at the world's leading academic, biotechnology, clinical diagnostic, government, medical centers, and pharmaceutical institutions are using this systematic approach to bioinformatics to maximize R&D effectiveness, improve hypothesis resolution, isolate vital biomarkers, and even transform a failing clinical trial around while also minimizing computational workflow times and data storage costs.

Read More

Research

Chemistry42, an AI System from Insilico, has been Incorporated into UCB's Drug Discovery Programmes

Insilico Medicine | March 15, 2021

Insilico Medicine, an AI drug discovery company, reported that UCB will incorporate Insilico's Chemistry42™ into UCB's inward drug discovery pipeline. UCB's initial appropriation of Insilico Medicine's restrictive innovation will give UCB's researchers the capacity to plan novel hit compounds that fulfill various predefined boundaries quickly and smooth out lead enhancement. With the Chemistry42™ platform, UCB researchers will likewise lessen the endeavors and expenses commonly connected with the plan, testing and commercialization of new drugs. Chemistry42™ v1.0 will be modified and conveyed on UCB's cloud-based supercomputing infrastructure. Chemistry42™ is an adaptable, easy to understand programming platform that incorporates man-made brainpower (AI) strategies with the fields of therapeutic and computational science for the plan of novel little atoms with client characterized druglike physicochemical properties. The platform is an adaptable conveyed web application equipped for running various assignments in equal very quickly. Container coordination and work process the executives consider unsurprising equipment freethinker asset distribution and the execution on one or the other cloud or neighborhood HPC infrastructures. "UCB is one of the leading companies in small molecule drug discovery. It was their insight and approach at the forefront of this science that encouraged us to move into AI-powered chemistry over five years ago and it gives me great pleasure to see UCB among the launch partners of our Chemistry42 operating system," said Alex Zhavoronkov, Ph.D., CEO of Insilico Medicine. "Insilico Medicine has been very responsive in this quickly developing area of science and we are delighted to be one of the launch partners for Chemistry42," Jiye Shi, Global Head of Computer-Aided Drug Design at UCB said. "Our hope is that this platform will further enhance the digital transformation of our drug discovery capabilities for the benefit of patients worldwide." About Insilico Medicine Insilico Medicine develops software that leverages generative models, reinforcement learning (RL), and other modern machine learning techniques to generate new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trial outcomes. The company integrates two business models: providing AI-powered drug discovery services and software through its Pharma.AI platform (www.insilico.com/platform/) and developing its pipeline of preclinical programs. The preclinical program is the result of pursuing novel drug targets and novel molecules discovered through its platforms. Since its inception in 2014, Insilico Medicine has raised over $52 million and received multiple industry awards. About UCB UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Read More

Events